iTRAQ-based proteomic identification of leucine-rich α-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases

• DOI: 10.1136/ard.2009.118919
• Publication Date: 2009-10-24T00:13:19Z
• Authors: Satoshi Serada; Minoru Fujimoto; Atsushi Ogata; Fumitaka Terabe; Toru Hirano; Hideki Iijima; Shinichiro Shinzaki; Teppei Nishikawa; Tomoharu Ohkawara; Kota Iwahori; Nobuyuki Ohguro; Tadamitsu Kishimoto; Tetsuji Naka
• Keywords: Proteomics; 0301 basic medicine; Tumor Necrosis Factor-alpha; Behcet Syndrome; Antibodies, Monoclonal; Reproducibility of Results; Enzyme-Linked Immunosorbent Assay; Blood Proteins; Infliximab; Autoimmune Diseases; 3. Good health; Arthritis, Rheumatoid; 03 medical and health sciences; C-Reactive Protein; Crohn Disease; Antirheumatic Agents; Humans; Biomarkers; Glycoproteins

<h3>Objective</h3> To identify a novel serum biomarker of disease activity in inflammatory autoimmune disorders. <h3>Methods</h3> Sera obtained from rheumatoid arthritis (RA) patients before and after anti-TNF therapy were analysed by iTRAQ (isobaric tags for relative absolute quantitation) quantitative proteomic analysis further validated ELISA. <h3>Results</h3> Of 326 proteins identified analysis, increased levels leucine-rich α-2 glycoprotein (LRG) was RA therapy. Serum LRG concentrations significantly elevated compared with healthy controls decreased Furthermore, correlated Crohn9s (CD). Interestingly, subpopulation active CD normal C-reactive protein levels, elevated. <h3>Conclusions</h3> represents monitoring during patients, particularly useful but CRP levels.